The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지

Effects of Gamisaenggan-tang on High Fat Diet-induced Nonalcoholic Fatty Liver Disease

가미생간탕(加味生肝湯)이 고지방식이로 유발된 지방간에 미치는 영향

  • Choi, Mi-Young (Dept. of Internal Medicine, College of Oriental Medicine, Kyung-hee University) ;
  • Woo, Hong-Jung (Dept. of Internal Medicine, College of Oriental Medicine, Kyung-hee University) ;
  • Kim, Young-Chul (Dept. of Internal Medicine, College of Oriental Medicine, Kyung-hee University) ;
  • Lee, Jang-Hoon (Dept. of Internal Medicine, College of Oriental Medicine, Kyung-hee University)
  • 최미영 (경희대학교 한의과대학 간계내과학교실) ;
  • 우홍정 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실)
  • Published : 2009.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The aim of this study was to investigate the effects of Gamisaenggan-tang on high fat diet induced nonalcoholic fatty liver disease. Methods: Rats were randomly divided into four groups. The Normal group was fed a solid diet containing 10% fat. The Gamisaenggan-tang (GS) group was fed a solid diet containing 10% fat and Gamisaenggan-tang (90mg/100g body weight). The Control group was fed a solid diet containing 60% fat. The HFD-Gamisaenggan-tang (HFD-GS) group was fed a solid diet containing 60% fat and Gamisaenggan-tang (90mg/100g body weight). Six weeks later, rats body weight, liver weight, serum ALT, GGT, ALP levels were measured. Histological findings (Oil red O staining), hepatic triglyceride, TNF-${\alpha}$, and TGF-${\beta}$ levels in the liver tissue were studied. Results: Average body weight of the HFD-GS group was significantly less than that of the Control group. There were no significant liver weight differences among each group. The GGT levels of the HFD-GS group were significantly less than those of the Control group. However, there were no significant differences in the ALT or ALP levels among the groups. TNF-${\alpha}$ protein production assessed by western blot analysis was reduced by Gamisaenggan-tang. Greater fat accumulation was observed in the liver tissue of the Control group than in the HFD-GS group, which means the Gamisaenggan-tang has an inhibitory effect on the accumulation of fat in the liver. Conclusion : The results suggest that Gamisaenggan-tang can be potential candidate for the treatment of nonalcoholic fatty liver disease in clinics.

Keywords

References

  1. Yan E, Durazo F, Tong M, Hong K. Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutr Rev. 2007; 65(8):376-84. https://doi.org/10.1111/j.1753-4887.2007.tb00315.x
  2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-38.
  3. 정재연. 비알코올성 지방간질환의 치료. 대한간학회지. 2007;13(2s):9-16.
  4. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatolgy. 2005;42(1):44-52.
  5. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in woman with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;5(4):496-501. https://doi.org/10.1016/j.cgh.2006.10.010
  6. Damaso AR, do Prado WL, de Piano A, Tock L, Caranti DA, Lofrano MC, Carnier J, Cristofalo DJ, Lederman H, Tufik S, de Mello MT. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis. 2008;40(2):132-9. https://doi.org/10.1016/j.dld.2007.09.009
  7. SanYal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contons MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis : Association of insulin resistance and mitochodrial abnormalities. Gastroenterolgy. 2001;120(5):1183-92. https://doi.org/10.1053/gast.2001.23256
  8. 김홍규, 서찬종, 윤효종, 황용하, 이기영, 박혜영, 김갑환, 강문호. 비알코올성 지방간과 대사성질 환들과의 연관성. 대한내분비학회지. 2002;17(4): 526-34.
  9. 유권. 비알콜성 지방간염. 대한간학회지. 2002; 8(1s):66-72.
  10. 김선미, 김정아, 한지혜, 조경환, 윤도경. 당뇨가 없고 정상체중을 가진 사람에서 비알코올성 지방간 질환과 대사성 증후군. 대한비만학회지. 2006;15(1):44-51.
  11. Charles S Lieber, Maria A Leo, Ki M Mak, Youqing Xu, Qi Cao, Chaoling Ren, Anatoly Ponomarenko, Leonore M DeCarli. Model of nonalcoholic steatohepatits. 2004;79(3):502-9.
  12. 박상훈. 비알코올성 지방간염의 발병기전과 치료. 대한간학회지. 2008;14(1):12-27.
  13. 박원환. 마취유무에 따른 章門・期門穴의 울금 약침이 고지방성 식이로 인한 고지혈증 白鼠에 미치는 영향. 대한동의병리학회지. 1999;13(1): 92-103.
  14. 반상석, 윤현덕, 신오철, 신유정, 박치상, 박지하, 서부일. 고지방 식이로 유도된 비만 흰쥐에 茵蔯, 枳實, 山査가 미치는 영향. 대한본초학회지. 2006;21(3):55-67.
  15. 김형철, 김형우, 조수인, 김용성, 이장식, 권정남, 김영균. 丹蔘이 고지혈증 흰쥐의 혈중 지질 변화에 미치는 영향. 대한본초학회지. 2007; 22(4):239-45.
  16. 吳其愷, 程井軍, 聶广. 脂炎消煎劑治療非酒精性 脂肪肝 63例的臨床觀察. CJ GMTCM. 2007; 22(2):34-5.
  17. 趙和平, 段曉燕. 降脂益肝冲劑治療非酒精性脂肪 肝炎的實驗硏究. Drug evaluation. 2007;4(2):114-6
  18. 지형준. 대한약전 및 대한약전외 한약규격주해. 서울: 한국메디칼인덱스사; 1998. p. 109-619.
  19. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31. https://doi.org/10.1056/NEJMra011775
  20. 박중원. 지방간의 진단과 치료. 대한간학회지. 2001;7(1s):64-70.
  21. 전국한의과대학 간계내과학 교수 공저. 간계내과학. 서울: 동양의학연구원;2001. p. 315-22.
  22. 류광렬, 김철우, 이지은, 한창우, 김영철, 이장훈, 우홍정. 만성 B형간염환자에서 자발성 급성 학화 2례. 대한한방내과학회 추계학술대회. 2004;73-81.
  23. 이창규. 生肝湯이 $CCl_4$ 및 d-galactosamine에 의하여 유발된 흰쥐의 간장해에 미치는 영향. 경희대학교 대학원. 1986.
  24. 최서형. 生肝湯과 그 분획이 간장보호, 혈소판 응집능 및 일반 면역기능에 미치는 영향. 경희대학교 대학원. 1987.
  25. 류경하. 生肝湯이 고지혈증에 미치는 영향. 경희대학교 대학원. 1988.
  26. 승현석, 박신명, 한창우, 김영철, 이장훈, 우홍정. 加減生肝湯을 투여하여 호전된 급성 간염 2례. 대한한방내과학회. 2002;23(2):226-37.
  27. 김영철, 이장훈, 우홍정. 중풍을 동반한 초기간 경변증 치험 1례. 대한한방내과학회 별책부록. 1999;19(2):21-8.
  28. 김동우, 김덕호, 우홍정, 김병운. 加減生肝湯을 투여한 간암환자에 관한 연구. 대한한의학회지. 1991;12(2):233-49.
  29. Baumgardner JN, shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G27-38.
  30. Xue Zhi Hong, Lian Da, Li Mao Wu. effect of fenofibrate and xuezhikang on high-fat diet-induced nonalcoholic fatty liver disease. Clinical and experimental pharmacology and physiology. 2007;34:27-35. https://doi.org/10.1111/j.1440-1681.2007.04547.x